糖心vlog

Key Points

Question听 Do specific organ systems manifest poor health in individuals with common neuropsychiatric disorders?

Findings听 This multicenter population-based cohort study including 85鈥�748 adults with neuropsychiatric disorders and 87鈥�420 healthy control individuals found that poor body health, particularly of the metabolic, hepatic, and immune systems, was a more marked manifestation of mental illness than brain changes. However, neuroimaging phenotypes enabled differentiation between distinct neuropsychiatric diagnoses.

Meaning听 Management of serious neuropsychiatric disorders should acknowledge the importance of poor physical health and target restoration of both brain and body function.

Importance听 Physical health and chronic medical comorbidities are underestimated, inadequately treated, and often overlooked in psychiatry. A multiorgan, systemwide characterization of brain and body health in neuropsychiatric disorders may enable systematic evaluation of brain-body health status in patients and potentially identify new therapeutic targets.

Objective听 To evaluate the health status of the brain and 7 body systems across common neuropsychiatric disorders.

Design, Setting, and Participants听 Brain imaging phenotypes, physiological measures, and blood- and urine-based markers were harmonized across multiple population-based neuroimaging biobanks in the US, UK, and Australia, including UK Biobank; Australian Schizophrenia Research Bank; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer鈥檚 Disease Neuroimaging Initiative; Prospective Imaging Study of Ageing; Human Connectome Project鈥揧oung Adult; and Human Connectome Project鈥揂ging. Cross-sectional data acquired between March 2006 and December 2020 were used to study organ health. Data were analyzed from October 18, 2021, to July 21, 2022. Adults aged 18 to 95 years with a lifetime diagnosis of 1 or more common neuropsychiatric disorders, including schizophrenia, bipolar disorder, depression, generalized anxiety disorder, and a healthy comparison group were included.

Main Outcomes and Measures听 Deviations from normative reference ranges for composite health scores indexing the health and function of the brain and 7 body systems. Secondary outcomes included accuracy of classifying diagnoses (disease vs control) and differentiating between diagnoses (disease vs disease), measured using the area under the receiver operating characteristic curve (AUC).

Results听 There were 85鈥�748 participants with preselected neuropsychiatric disorders (36鈥�324 male) and 87鈥�420 healthy control individuals (40鈥�560 male) included in this study. Body health, especially scores indexing metabolic, hepatic, and immune health, deviated from normative reference ranges for all 4 neuropsychiatric disorders studied. Poor body health was a more pronounced illness manifestation compared to brain changes in schizophrenia (AUC for body鈥�=鈥�0.81 [95% CI, 0.79-0.82]; AUC for brain鈥�=鈥�0.79 [95% CI, 0.79-0.79]), bipolar disorder (AUC for body鈥�=鈥�0.67 [95% CI, 0.67-0.68]; AUC for brain鈥�=鈥�0.58 [95% CI, 0.57-0.58]), depression (AUC for body鈥�=鈥�0.67 [95% CI, 0.67-0.68]; AUC for brain鈥�=鈥�0.58 [95% CI, 0.58-0.58]), and anxiety (AUC for body鈥�=鈥�0.63 [95% CI, 0.63-0.63]; AUC for brain鈥�=鈥�0.57 [95% CI, 0.57-0.58]). However, brain health enabled more accurate differentiation between distinct neuropsychiatric diagnoses than body health (schizophrenia-other: mean AUC for body鈥�=鈥�0.70 [95% CI, 0.70-0.71] and mean AUC for brain鈥�=鈥�0.79 [95% CI, 0.79-0.80]; bipolar disorder-other: mean AUC for body鈥�=鈥�0.60 [95% CI, 0.59-0.60] and mean AUC for brain鈥�=鈥�0.65 [95% CI, 0.65-0.65]; depression-other: mean AUC for body鈥�=鈥�0.61 [95% CI, 0.60-0.63] and mean AUC for brain鈥�=鈥�0.65 [95% CI, 0.65-0.66]; anxiety-other: mean AUC for body鈥�=鈥�0.63 [95% CI, 0.62-0.63] and mean AUC for brain鈥�=鈥�0.66 [95% CI, 0.65-0.66).

Conclusions and Relevance听 In this cross-sectional study, neuropsychiatric disorders shared a substantial and largely overlapping imprint of poor body health. Routinely monitoring body health and integrated physical and mental health care may help reduce the adverse effect of physical comorbidity in people with mental illness.

Mental illness is associated with higher rates of chronic physical illness, including coronary heart disease, obesity, and diabetes,^1,2 compared to the general population. This contributes substantially to the global health and economic burden due to increased morbidity, disability, and mortality.^3,4 Yet in psychiatric care and services, physical health has been neglected and inadequately managed for decades.¹

Despite increased awareness of physical health in psychiatry,^5,6 recognizing and treating chronic physical illness remains a challenge. Poor physical health in patients is likely underestimated due to existing disparities in health care for people with mental illness, such as lack of access to adequate primary care,⁷ diagnostic overshadowing,^8,9 and difficulties with acknowledging¹⁰ and reporting medical problems for some patients.^11,12 Further work is thus needed to understand associations between mental and physical comorbidities, which may facilitate holistic and integrated care in psychiatry.

Most meta-research has focused on cardiovascular and metabolic comorbidities in psychiatry, as summarized in a review by Firth and colleagues.⁵ While infectious¹³ and immune-related comorbidities^14,15 have also been investigated, the chronic illness burden of common diseases affecting other body systems is scarcely explored.^6,16 The association between brain and body health as well as the associated disease risk and physical multimorbidity across body systems hence remain poorly characterized.

We systematically investigated brain and body health in common neuropsychiatric conditions (ie, schizophrenia, bipolar disorder, depression, and generalized anxiety disorder). Using brain images, physiological measures, and blood- and urine-based markers acquired in more than 100鈥�000 individuals, we established composite organ health scores for 2 brain and 7 body systems. We computed age- and sex-specific normative reference ranges for each organ鈥檚 health score based on healthy comparison individuals and quantified the extent to which individuals with the above conditions deviated from the established normative ranges. This enabled us to develop multiorgan health profiles for each neuropsychiatric condition and estimate the relative effect of these profiles in each individual鈥檚 body systems and physical health. We suggest that the management of serious neuropsychiatric disorders should acknowledge the importance of physical health and target restoration of both brain and body function.

This study integrated brain imaging data (structural and diffusion-weighted magnetic resonance imaging [MRI]) with physical and physiological data (where available) acquired from individuals participating in the following consortia studies from March 2006 to December 2020: UK Biobank; Australian Schizophrenia Research Bank; Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing; the Alzheimer Disease Neuroimaging Initiative; the Prospective Imaging Study of Ageing; the Human Connectome Project鈥揧oung Adult; and the Human Connectome Project鈥揂ging. All data are cross-sectional. T1-weighted MRI brain images were available for 22鈥�005 individuals aged 18 to 95 years collectively sourced from the 7 consortia, and diffusion-weighted MRI brain images were available for 20鈥�283 individuals (mean [SD]; range age, (60.6 [11.5]; 18-95 years) from all cohorts except the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Physical and physiological assessments were sourced from 175鈥�944 individuals (mean [SD]; range age, 54.8 [8.1]; 37-74 years) participating in UK Biobank.

Ethical approval was obtained as follows: for UK Biobank, from the North West Multi-centre Research Ethics Committee; the Australian Schizophrenia Research Bank, Melbourne Health Human Research Committee (Project ID: 2010.250); the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing, the institutional ethics committees of Austin Health, St Vincent鈥檚 Health, Hollywood Private Hospital and Edith Cowan University; the Alzheimer鈥檚 Disease Neuroimaging Initiative, according to the ethical standards of the institutional and/or national research committee of each site and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards; Prospective Imaging Study of Ageing, from the Human Research Ethics Committees of QIMR Berghofer Medical Research Institute and the University of Queensland; Human Connectome Project, the Washington University鈥揢niversity of Minnesota Human Connectome Project consortium. Details pertaining to each cohort are described in eMethods in Supplement 1. Written informed consent was obtained from all participants. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology () reporting guideline.

Regionally specific brain phenotypes derived from T1-weighted MRI, including cortical thickness and cortical and subcortical gray matter (GM) volume were selected to profile brain GM health (eTable 1 in Supplement 1). Brain white matter (WM) health was profiled using tract-specific measures of WM microstructure, including fractional anisotropy and mean diffusivity (eTable 2 in Supplement 1). Data were harmonized using ComBat^17,18 to control for site and scanner variation. Details of imaging processing, quality control, and phenotype extraction are described in eMethods in Supplement 1.

Physical assessments and blood and urine sample assays were available for UK Biobank participants. Assessment details and procedures for processing biological samples are described elsewhere.¹⁹ Physical and physiological measures known to inform the function and health of 7 body systems were selected and grouped into pulmonary, musculoskeletal, kidney, metabolic, hepatic, cardiovascular, and immune systems (eFigure 1A and eTable 3 in Supplement 1). Data curation and the handling of missing data are described in eMethods in Supplement 1.

Following previous work,²⁰ generalized additive models for location, scale, and shape were used to establish sex-specific normative reference ranges (mean and centiles) across the adult life span for each brain and body phenotype (eFigure 1B in Supplement 1), based on individuals without any neuropsychiatric illness or other serious medical conditions (eMethods in Supplement 1). The normative reference ranges were then used to estimate standardized phenotypic deviation scores (z scores) for individuals with a neuropsychiatric disorder (schizophrenia, bipolar disorder, depression, or generalized anxiety disorder).^21,22 A deviation score was estimated separately for each brain and body phenotype (age and sex specific), quantifying the number of standard deviations an individual deviated from the reference median. Deviation scores for healthy individuals were estimated using 10-fold cross-validation (eMethods in Supplement 1).

A principled approach was developed to summarize phenotypic deviation scores at an organ system level to enable systematic mapping of multisystem health profiles. Phenotypes were grouped based on relevance to the health and function of 2 brain systems (GM and WM) (eTables 1 and 2 in Supplement 1) and 7 body systems (pulmonary, musculoskeletal, kidney, metabolic, hepatic, cardiovascular, and immune) (eTable 3 in Supplement 1). Deviations from the established normative ranges for all phenotypes relevant to a particular system were subsequently combined to yield a single organ-specific health score (OHS) for each system and individual, excluding those with comorbid psychiatric conditions. Health scores were calibrated such that OHS鈥�=鈥�0 indicates the median of healthy, normal organ function and OHS鈥�<鈥�0 suggests a potential deterioration of organ health, controlling for age and sex.

For example, to estimate phenotype weights for the metabolic health score, the patient group comprised individuals diagnosed with chronic metabolic diseases, including diabetes and disorders of lipoprotein metabolism (eMethods and eTable 4 in Supplement 1). In this way, phenotypes differentiating chronic metabolic diseases were weighted highly when computing the composite metabolic health score and analogously for the other organ systems (eFigure 1C in Supplement 1). The phenotype weights were then used to compute organ health scores for individuals with 1 or more neuropsychiatric disorders (eMethods and eTables 5-9 in Supplement 1).

Ten-fold cross-validation was performed to ensure that organ health scores were not computed for the same individuals who were used to estimate phenotype weights. A composite body health score was also computed using all body phenotypes. Differences in organ health scores between disorder groups and the healthy comparison group were tested using analysis of covariance, adjusting for age and sex. The false discovery rate (FDR) was using the Benjamini-Hochberg procedure across 4 disorder groups鈥壝椻��10 organ systems鈥�=鈥�40 tests. Cross-validated logistic regression models were trained to classify an individual鈥檚 diagnostic status based on phenotypic deviation scores (eFigure 1D and eMethods in Supplement 1).

There were 85鈥�748 participants with preselected neuropsychiatric disorders (36鈥�324 male) and 87鈥�420 healthy control individuals (40鈥�560 male) included in this study. The Table provides demographic and clinical characteristics.

Normative reference ranges across the adult life span were established for 203 imaging, blood, urine, and physiological markers. Phenotypic variation was best modeled by the Box-Cox t distribution compared to the other 20 distribution families evaluated (eFigure 2 in Supplement 1). Both linear and nonlinear patterns of age-related trajectories were captured across different phenotypes (eFigure 3 in Supplement 1).

We found that all organ-specific health scores were on average significantly lower in individuals with neuropsychiatric disorders compared to age- and sex-matched healthy peers (Figures 1 and 2; eFigures 4-6 in Supplement 1). Specifically, body health scores were markedly lower for individuals with schizophrenia (mean [SD] OHS, 鈭�1.65 [1.80]), bipolar disorder (mean [SD] OHS, 鈭�0.81 [1.48]), depression (mean [SD] OHS, 鈭�0.80 [1.49]), and generalized anxiety disorder (mean [SD] OHS, 鈭�0.53 [1.35]) compared to healthy individuals. Consistent across the 4 disorders, poor organ health was most evident for the metabolic system (mean OHS range: 鈭�1.24 to 鈭�0.45), hepatic system (mean OHS range: 鈭�0.85 to 鈭�0.21), immune system (mean OHS range: 鈭�0.65 to 鈭�0.19), and kidney system (mean OHS range: 鈭�0.37 to 鈭�0.12) (Figure 2).

Of the disorders studied, brain health was poorest in individuals with schizophrenia (mean [SD] GM/WM OHS, 鈭�0.37 [0.63]/鈭�0.12 [0.67]). In contrast, bipolar disorder (mean [SD] GM/WM OHS, 鈭�0.11 [0.62]/鈭�0.16 [0.52]), depression (mean [SD] GM/WM OHS, 鈭�0.14 [0.77]/鈭�0.15 [0.65]), and generalized anxiety disorder (mean [SD] GM/WM OHS, 鈭�0.10 [0.53]/鈭�0.10 [0.45]) groups showed only marginally poorer brain health relative to healthy control individuals. The effect sizes observed in brain health scores were consistent with subtle structural brain changes observed in individuals with bipolar disorder, depression, or anxiety,^23-26 while effect sizes for schizophrenia were relatively small to moderate.^27,28 Body health was on average poorer than brain health in these patients, which may be partly explained by physical comorbidities (eFigure 7 in Supplement 1).

Despite the neural basis of the included disorders, we found that body phenotypes provided the most accurate diagnostic classification for schizophrenia (area under the receiver operating characteristic curve [AUC], 0.81; 95% CI, 0.79-0.82), bipolar disorder (AUC, 0.67; 95% CI, 0.67-0.68), depression (AUC, 0.67; 95% CI, 0.67-0.67), and generalized anxiety disorder (AUC鈥�=鈥�0.63; 95% CI, 0.63-0.63) compared to both brain phenotypes (AUC for schizophrenia鈥�=鈥�0.79 [95% CI, 0.79-0.79], bipolar disorder鈥�=鈥�0.58 [95% CI, 0.57-0.58], depression鈥�=鈥�0.58 [95% CI, 0.58-0.58], and anxiety鈥�=鈥�0.57 [95% CI, 0.57-0.58]) and individual body systems (Figure 3A). When examining whether deviations of brain or body phenotypes would most accurately differentiate 2 neuropsychiatric diagnoses (transdiagnostic), we found that brain phenotypes substantially outperformed body phenotypes (schizophrenia-other: mean AUC for body鈥�=鈥�0.70 [95% CI, 0.70-0.71] and mean AUC for brain鈥�=鈥�0.79 [95% CI, 0.79-0.79]; bipolar disorder-other: mean AUC for body鈥�=鈥�0.60 [95% CI, 0.59-0.60] and mean AUC for brain鈥�=鈥�0.65 [95% CI, 0.65-0.65]; depression-other: mean AUC for body鈥�=鈥�0.61 [95% CI, 0.60-0.63] and mean AUC for brain鈥�=鈥�0.65 [95% CI, 0.65-0.66]; anxiety-other: mean AUC for body鈥�=鈥�0.63 [95% CI, 0.62-0.63] and mean AUC for brain鈥�=鈥�0.66 [95% CI, 0.65-0.66]) (Figure 3B).

Supplementary analyses were undertaken to contrast the above findings with organ health scores evaluated in a neurodegenerative condition (dementia). Similar to the above findings, we found that dementia manifested markedly poor body health (mean [SD] OHS, 鈭�1.61 [1.73]). Most people (6269/6506 [96.4%]) had not experienced dementia onset at the time of body function assessment. However, brain health was substantially poorer in individuals with dementia (mean [SD] GM/WM OHS, 鈭�0.59 [0.56]/鈭�0.20 [0.60]) compared to the 4 neuropsychiatric disorders studied (eFigures 4-6 in Supplement 1). Unlike these 4 neuropsychiatric disorders, we found that brain phenotypes outperformed all body systems for dementia classification (GM AUC, 0.91; 95% CI, 0.91-0.91 and WM AUC, 0.83; 95% CI, 0.83-0.84), although body phenotypes continued to provide modest diagnostic utility (AUC, 0.73; 95% CI, 0.72-0.73) (eFigure 8A in Supplement 1). This suggests that neurodegeneration was a more prominent manifestation of dementia compared to poor physical health. We also found that dementia was characterized by a distinct profile of brain deviations, enabling accurate differentiation from the other 4 diagnostic groups (mean GM AUC, 0.89; 95% CI, 0.89-0.89 and mean WM AUC, 0.81; 95% CI, 0.81-0.82) (eFigure 8B in Supplement 1). Pairwise transdiagnostic classification accuracies are shown in eFigure 9A and B in Supplement 1. High-ranked brain GM and WM phenotypes transdiagnostically associated with dementia are shown in eFigure 9C and D and eFigure 10 in Supplement 1.

In this cross-sectional study, by establishing normative models of brain and body function over the adult life span using population-based cohorts, we mapped multisystem health profiles for 4 common neuropsychiatric disorders. We showed that individuals diagnosed with these neuropsychiatric disorders were not only characterized by deviations from normative reference ranges for brain phenotypes but also presented considerably poorer physical health across multiple body systems compared to their healthy peers. Poor physical health was a more pronounced manifestation of neuropsychiatric illness than brain health. However, brain phenotypes enabled more accurate differentiation between pairs of neuropsychiatric diagnoses.

Despite profound deviations from established normative reference ranges for multiple body systems (eg, metabolic, hepatic, immune, and kidney), chronic physical comorbidities were often not diagnosed (eFigure 7 in Supplement 1), even years after body function assessment. Disparities in these physical health outcomes may reflect the lack of physical examination,^7,29 preventive screening, intervention,^30,31 and access to standard health care systems common among people with mental illness.⁵

Across the 4 neuropsychiatric disorder groups, the metabolic, hepatic, and immune systems consistently showed poor health scores. Poor metabolic health is consistent with the commonly reported increased risk of developing metabolic diseases, including diabetes,^32-34 metabolic syndrome,^35,36 and obesity,³⁷ in people with mental illness and may be partly attributable to adverse effects of antipsychotics³⁸ and chronic stress.^39,40 Chronic psychological stress is associated with mental illness and leads to dysregulation of the hypothalamic-pituitary-adrenal axis and endocrine and metabolic systems.^41-43 Hence, our findings of poor metabolic health in neuropsychiatric illness could be due to chronic stress exacerbating a genetic disposition for these conditions through dysregulation of metabolic and endocrine pathways. Poor hepatic health may be associated with excessive alcohol consumption,⁴⁴ higher rates of hepatitis B and hepatitis C infection,^13,45 and psychotropic drug-induced hepatotoxicity^46,47 in people with mental illness. In contrast, poor immune health could be a driver or consequence of the reciprocally increased risk between immune-inflammatory response and psychiatric disorders.^14,48,49 Although to a lesser extent, significantly poorer kidney health was also observed in these patients, which may in part relate to the adverse effects of mood stabilizers, especially lithium,^50,51 while poor pulmonary and musculoskeletal health may be associated with smoking,⁵² disease-related sedentary behaviors, physical inactivity,⁵³ and social withdrawal.⁵⁴

Poor body health may also be associated with premature aging in midlife. Biological brain age deviates from chronological age in a number of brain disorders.^55,56 This suggests a process of accelerated brain aging and may explain why some individuals manifest increased risk of age-related disease. To test these hypotheses, longitudinal studies are needed to determine the interplay between brain and body health throughout the course of psychiatric illness.

Whereas body phenotypes were generally more accurate than the brain in diagnostic classification, classification models for brain phenotypes outperformed all body systems in differentiating distinct diagnoses. Our models are not intended for disease classification under clinical settings, but rather provide an alternative and quantitative mapping of how brain and body systems may be differentially affected in neuropsychiatric conditions. Our results suggest that patterns of abnormal deviations in brain GM and WM were relatively distinct between different neuropsychiatric disorders. This distinction was strongest for schizophrenia compared to anxiety, depression, and bipolar disorder, where the latter 3 could not be accurately differentiated. This may be partly explained by the higher comorbidity rates among the 3 disorders compared to schizophrenia in the UK Biobank cohort (eMethods in Supplement 1), diagnostic instability,^57,58 and shared neurobiology and neural-behavior mechanisms^59-62 across the 3 disorders.

In supplementary analyses, to provide a point of reference, we compared our findings of poor body health to a common neurodegenerative condition (ie, dementia). We found that dementia manifested the poorest brain and body health of all the disorders studied (eFigure 4 in Supplement 1). Although dementia is often associated with progressive GM loss,^63,64 the most extreme deviations from normative ranges were observed in the metabolic and hepatic systems (eFigure 5 in Supplement 1), consistent with the 4 neuropsychiatric conditions. The combination of insulin resistance and hepatic dysfunction in dementia has been hypothesized to lead to inadequate clearance from the brain of amyloid and toxic metabolites produced by the liver, which cross the blood-brain barrier,⁶⁵ leading to brain inflammation and pathology. Of note, body phenotypes were assessed when participants were relatively young (Table) and had not experienced dementia onset or diagnosis (prodromal, 6269/6506 [96.4%]) at the time of body function assessment. Our results suggest that physical health may have deteriorated in these individuals, possibly contributing to the risk of developing dementia later in life.^66,67 Prospective studies are needed to track organ health throughout the life span and identify when body and brain systems first deviate from the normative reference ranges established here. Future work is also needed to test whether our organ health scores, especially the metabolic and hepatic health scores, can predict dementia onset and enable early identification of individuals at risk of dementia.

Our findings provide biological evidence supporting the adoption of established preventive public health principles and strategies commonly used in the general population for physical illness (eg, Diabetes Prevention Program⁶⁸) in psychiatry care to complement disease-specific psychotropic medication and psychological treatments. This may be a cost-effective way to reduce disease burden and mortality across neuropsychiatric conditions.⁵

The physical health of people with mental illness needs to be routinely assessed and adequately managed to reduce morbidity and mortality and improve patient well-being.^1,31 The organ-specific health scores developed in our study enabled a systematic and holistic evaluation of brain-body health status in people with common neuropsychiatric disorders. Further work is needed to determine whether our organ health scores enable prediction of physical comorbidity in advance of disease onset and identification of individuals at risk of developing physical illness. This in turn could drive new preventive strategies.

This study has limitations. Body phenotypes were only available in 1 cohort (UK Biobank), and participants in this cohort had a narrower age range (37 to 74 years) than in other cohorts (18 to 95 years). This limited a comprehensive characterization of age-related changes in body systems across the adult life span. Brain health scores were restricted to MRI-derived phenotypes. Inclusion of neuroimaging phenotypes such as magnetic resonance spectroscopy of cerebral metabolites^69,70 would complement the MRI-derived phenotypes used here and further characterize brain health in a way that that might be more sensitive to early brain dysfunction. Nevertheless, MRI scans and other physiological markers comprising our organ health scores are already widely accessible in clinical and primary care settings, facilitating direct, cost-effective, and feasible clinical implementation. Further, a within-individual comparison of brain and body health deviations was not feasible, because not all brain and body phenotypes were available for all individuals. It is also important to acknowledge biases inherent to the cohorts studied. UK Biobank predominantly comprises individuals of White British ancestry, and further work is needed to test our models in individuals of various races and ethnicities. Individuals with serious illness may have been unable or less likely to participate in certain assessments, yielding sampling biases in disease cohorts and underestimation of illness severity and comorbidities.⁷¹

In this study, marked deviations from normative reference ranges for brain and body health were evident across multiple organ systems in people with neuropsychiatric disorders in this study. The metabolic, hepatic, and immune systems showed the poorest health and function for the disorders studied. Despite the unequivocal neural basis of common neuropsychiatric disorders, the findings of this study suggest that poor body health and function may be important illness manifestations that require ongoing treatment in patients. Routinely monitoring body health and integrated physical and mental health care in psychiatric practice may provide cost-effective targets for reducing the adverse effect of physical comorbidity in people with mental illness.

Accepted for Publication: February 15, 2023.

Published Online: April 26, 2023. doi:10.1001/jamapsychiatry.2023.0791

Corresponding Author: Ye Ella Tian, MBBS, PhD, Department of Psychiatry, Melbourne Neuropsychiatry Centre, Melbourne Medical School, the University of Melbourne, Level 3, Alan Gilbert Building, 161 Barry St, Carlton, Melbourne, Victoria, 3053, Australia (ye.tian2@unimelb.edu.au).

Author Contributions: Dr Tian had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analyses.

Concept and design: Tian, Zalesky.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Tian, Zalesky.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Tian, Zalesky.

Obtained funding: Tian, Zalesky.

Administrative, technical, or material support: Tian, Mosley, Lupton, Breakspear, Zalesky.

Supervision: Cropley, Zalesky.

Conflict of Interest Disclosures: Dr Zalesky reported grants from National Health and Medical Research Council Senior Research Fellowship during the conduct of the study. No other disclosures were reported.

Funding/Support: Dr Tian was supported by the Mary Lugton Postdoctoral Fellowship. Dr Zalesky was supported by the Senior Rebecca L. Cooper Fellowship. Dr Cropley was supported by National Health and Medical Research Council grant APP1177370. Dr Breakspear was supported by National Health and Medical Research Council grant APP2008612. Some of the data collection and sharing for this project was funded by the Alzheimer鈥檚 Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and Department of Defense ADNI (Department of Defense award number W81XWH-12-2-0012).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 2.

Additional Contributions: Some of the data used in the preparation of this article were obtained from the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (AIBL), funded by the Commonwealth Scientific and Industrial Research Organisation, which was made available at the Alzheimer鈥檚 Disease Neuroimaging Initiative (ADNI) database (). The AIBL researchers contributed data but did not participate in analysis or writing of this report. AIBL researchers are listed at: . Some of the data used in preparation of this article were obtained from the ADNI database (). As such, the investigators within the ADNI contributed to the design and implementation of ADNI or provided data but did not participate in analysis or writing of this report. A complete list of ADNI investigators can be found at: . We thank the chief investigators of the Australian Schizophrenia Research Bank: Vaughan Carr, Ulrich Schall, Rodney Scott, Assen Jablensky, Bryan Wowry, Patricia Michie, Stanley Catts, Frans Henskens, Christos Pantelis, Carmel Loughland. The Australian Schizophrenia Research Bank chief investigators did not participate in analysis or writing of this report. Some of the data were curated and analyzed using the Linkage Infrastructure, Equipment and Facilities鈥擥eneral Purpose Graphics Processing Unit facility hosted at the University of Melbourne, Parkville, Victoria, Australia. This facility was established with the assistance of LIEF grant LE170100200.

Additional Information: We acknowledge UK Biobank, a major biomedical database, the Human Connectome Project, and the National Institute of Mental Health data archive. Alzheimer鈥檚 Disease Neuroimaging Initiative is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, AbbVie, Alzheimer鈥檚 Association, Alzheimer鈥檚 Drug Discovery Foundation, Araclon Biotech, BioClinica, Biogen, Bristol Myers Squibb, CereSpir, Cogstate, Eisai, Elan Pharmaceuticals, Eli Lilly, EuroImmun, F. Hoffmann-La Roche and its affiliated company Genentech, Fujirebio, GE Healthcare, IXICO, Janssen Alzheimer Immunotherapy Research & Development, Johnson & Johnson Pharmaceutical Research & Development, Lumosity, Lundbeck, Merck, Meso Scale Diagnostics, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer, Piramal Imaging, Servier, Takeda Pharmaceutical Company, and Transition Therapeutics. The Canadian Institutes of Health Research provides funds to support Alzheimer鈥檚 Disease Neuroimaging Initiative clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer鈥檚 Therapeutic Research Institute at the University of Southern California, Los Angeles. Alzheimer鈥檚 Disease Neuroimaging Initiative data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California, Los Angeles. Some of the data used in preparation of this article were obtained from the Prospective Imaging Study of Ageing: Genes, Brain and Behaviour database, funded by the National Health and Medical Research Council (APP1095227) of the Australian Government. Some of the data used in the preparation of this article were obtained from the Australian Schizophrenia Research Bank. The Australian Schizophrenia Research Bank is supported by the National Health and Medical Research Council of Australia, the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute.